News

Medscape12d
Amlodipine Besylate Vs. Candesartan Cilexetil - Page 5
Clin Drug Invest. 2005;25 (9):567-577. Conclusions Both therapeutic regimens (amlodipine besylate and candesartan cilexetil) were very effective in lowering office BP after 12 weeks of treatment.
Medscape12d
Amlodipine Besylate Vs. Candesartan Cilexetil - Page 2
The treatment medications supplied for the study were amlodipine besylate 5 and 10mg tablets, candesartan cilexetil 8 and 16mg capsules, placebo matching the amlodipine tablets and placebo ...
Pharmabiz10d
Aspire Biopharma enrolls last patient in phase 1 trial of its oral transmucosal fast-acting high-dose aspirin formulation
Aspire Biopharma Holdings, Inc, developer of a multi-faceted patent-pending drug delivery technology, announced the last patient was dosed in its phase 1 single-center clinical study of its oral ...
Yahoo Finance12d
Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation - Yahoo Finance
Enrollment Completed on Schedule; Topline Results Expected Mid Q3 2025 ESTERO, FL AND NEW YORK, NY / ACCESS Newswire / June 24, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or ...
Tri-City Herald12d
Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation - Tri-City Herald
Contact TraDigital IR Kevin McGrath +1-646-418-7002 kevin@tradigitalir.com SOURCE: Aspire Biopharma Holdings, Inc. This story was originally published June 24, 2025 at 5:32 AM.
Fort Worth Star-Telegram12d
Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation - Fort Worth Star ...
Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation ACCESS Newswire Updated June 24, 2025 7:41 AM ...